Tillman Gerngross, Adagio Therapeutics CEO
July 16, 2020 08:00 AM EDT
Startups
Bioregnum
Opinion

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

One of the most in­flu­en­tial — and out­spo­ken — sci­en­tists at work in the field of an­ti­body dis­cov­ery is jump­ing in­to the fren­zied race to cre­ate new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Bi­par­ti­san 'pill penal­ty' fix and oth­er bills vie for in­clu­sion in rec­on­cil­i­a­tion pack­age

Can Bill An­der­son save Bay­er?

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times